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Recent  cases  of  avian  inﬂuenza  H7N9  have  caused  great  concerns  that virus  may  become  transmittable
between  humans.  It is imperative  to develop  an  effective  vaccine  to ﬁght  against  the  pandemic  potential
of  this  H7N9  inﬂuenza  virus  to  protect  human  from  the  disease.  This  study  aims  to investigate  an  opti-
mized  formulation  for the  development  of H7N9  vaccines.  Various  doses  of H7N9  inactivated  whole  or
split-virus  antigens  (0.5, 1.5,  or 3 g based  on  hemagglutinin  content)  combined  with  squalene-based
adjuvant  (AddaVAX),  aluminum  hydroxide  Al(OH)3 or without  adjuvant  were  evaluated  for  the  efﬁcacy
of H7N9  vaccine  regiments  in mice.  With  either  H7N9  whole  or split-virus  based  vaccines,  AddaVAX-
adjuvanted  formulations  were  the most  immunogenic  in eliciting  signiﬁcant  humoral  immune  response
against  H7N9  virus  and  exhibited  strong  cross-reactive  response  in hemagglutination  inhibition  (HAI)  and
viral-neutralization  assays  against  H7N7  virus  as  well.  In  contrast,  formulations  with  Al(OH)3 or  without
adjuvant  were  less  immunogenic  and  elicited  lower  titers  of HAI  and  microneutralization  assays  against
both  viruses.  Dose-sparing  experiments  suggested  that  the  formulation  with  as  low  as  0.004  g of  split  or
whole virus  vaccine  antigens  together  with  50% AddaVAX  provided  sufﬁcient  sero-protective  HAI  titers
and  achieved  essential  virus-neutralizing  antibody  titers  against  H7-subtype  inﬂuenza  viruses  in  mice.
Protection  experiments  demonstrated  that the  formulation  of  0.004  g to  0.5 g of  split-virion  vaccines
with  AddaVAX  conferred  full  protection  against  viral  challenge  up to 100  LD50  of wild-type  H7N9  virus,
with  0%  survival  in  placebo  group.  Taken  together,  our  study  demonstrates  that  squalene-based  adjuvant
can  signiﬁcantly  enhance  the protective  efﬁcacy  of H7N9  virus  vaccine  and  provides  a useful  strategy  to
confront  the  potential  pandemic  outbreaks  of H7N9  virus.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Human infection with a newly emerged avian-origin inﬂuenza
/H7N9 virus was ﬁrst conﬁrmed in March 31, 2013, in China [1].
o date there have been 251 cases of human infection caused by
7N9 virus in twelve provinces and two municipalities in China,
ith 20–30% mortality rate among infected individuals. A case of
evere illness imported from China was also conﬁrmed in Taiwan in
ate summer, 2013 [2]. The clinical research reported that most of
atients infected with the novel H7N9 virus exhibit severe illness,
∗ Corresponding author. Tel.: +886 4 2538 1220x1223; fax: +886 4 2538 2105.
E-mail addresses: JR Chen@adimmune.com.tw, juinerueychen@gmail.com
J.-R. Chen).
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
including pneumonia and acute respiratory distress syndrome,
with high rates of intensive care unit admission or death, suggesting
it is highly pathogenic and high fatality rate to human [1].
Recent evidence showed that the novel H7N9 virus is originally
zoonotic and may  be better adapted than other avian inﬂuenza
viruses such as H5N1 to infect human [1,3–6]. Although no direct
evidence has indicated the human-to-human transmission of the
avian-origin H7N9 virus, recent studies reported that the virus may
evolve to have the human-transmittable features through muta-
tion in receptor binding site or genetic reassortment, and possibly
results in a global pandemic in the future [7–11]. Comprehensive
surveillance and early diagnosis may  help to reduce the number
of cases and deaths in the suspected areas, but the virus spread
among animal reservoirs is difﬁcult to control since the infected
poultry may  display ignorable symptoms [3]. Vaccination is
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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onsidered to be the most effective way to prevent the transmis-
ion and the subsequent huge economic loss and human sufferings
aused by inﬂuenza pandemics; therefore it is urgently needed
o prepare an effective H7N9 inﬂuenza vaccine for the control of
otential pandemic outbreak.
Previous clinical study has shown the inactivated H7N7 sub-
ype inﬂuenza vaccine candidate is safe but poorly immunogenic in
uman trial when subjects were randomized to receive two doses
f 90 g of HA of an inactivated subunit inﬂuenza A (H7N7) vaccine
ntramuscularly [12]. The result indicates that the making of efﬁ-
acious H7N9 vaccine for human might need efforts to improve
he immunogenicity of viral antigens. In this study, the H7N9
nactivated virus vaccines were prepared to investigate the optimal
accine formulation in mice, including the different doses of anti-
ens combined with commonly used adjuvants and dose-sparing
ffect of adjuvanted-H7N9 vaccines. Our results demonstrated
hat squalene-adjuvanted virus vaccines containing antigens from
7N7 or H7N9 are both sufﬁcient to provide mice with high hemag-
lutination inhibition (HAI) titers and cross-neutralizing activity
gainst H7 subtype viruses. Immunogenicity studies revealed that
hile splitted or whole H7N7 virus vaccine induced similar level
f immune response, splitted H7N9 virus elicited higher immunity
han whole virus against H7-subtype viruses. This study provides
ew insights into the cross reactivity and protective immunity
onferred by squalene-adjuvanted H7 subtype virus vaccines and
eveals a general strategy for H7N9 vaccine design for future clinical
rials and human use.
. Materials and methods
.1. Cell, virus strains, and antibody
MDCK cells (CCL-34) obtained from the American Type Cul-
ure Collection were maintained in 1× DMEM supplemented
ith 5% fetal bovine serum (Thermo Scientiﬁc) in incubator
t 37 ◦C with 5% CO2. The new reassortant H7 vaccine strains,
ontaining six internal genes derived from A/PR/8/34 virus, were
btained from the Centers for Disease Control and Prevention
Atlanta, GA). The A/Shanghai/2/2013(H7N9)-IDCDC-RG32A
HA and NA were derived from A/Shanghai/2/2013(H7N9);
/Mallard/Netherlands/12/2000(H7N7)-IBCDC-1 (HA and NA
ere derived from A/Mallard/Netherlands/12/2000(H7N3) and
/Mallard/Netherlands/2/2000(H10N7), respectively); the wild-
ype inﬂuenza virus, A/Taiwan/01/2013(H7N9) (The gene of HA
nd NA has been sequenced and reported to WHO), was  obtained
rom the Centers for Disease Control, Taiwan. These viruses were
ropagated in chicken eggs or in MDCK cells for vaccine antigen
roduction, challenge assay, HAI assay, and microneutralization,
espectively.
.2. Vaccine preparation
Virus stocks were propagated in 10-day-old speciﬁc-pathogen-
ree embryonated chicken eggs at 34 ◦C. The infected allantonic
uids were harvested at 48 h post-inoculation and concentrated for
he clariﬁcation. The viruses were puriﬁed by using sucrose density
entrifugation in a 20%-to-50% (W/V) sucrose gradient for 1.5 h at
5,000 rpm at 4 ◦C. The inactivated whole virus vaccines were pre-
ared by treating with 0.05% -propiolactone (BPL) at 4 ◦C for 48 h.
he vaccines in a splitted form were prepared by ether treatment,
ollowed by 0.01% formalin inactivation. The inactivated vaccine
ntigens were veriﬁed for the absence of viral infectivity by serial
assages in eggs. (2014) 4485–4494
2.3. Hemagglutination inhibition assay (HAI)
To determine HAI titers, mice sera were treated with a receptor-
destroying enzyme (RDE) overnight and heat-inactivated for 1 h.
The sera were tested in 2-fold dilutions starting with an initial
dilution of 1:10, and then admixed with 4 HA units of H7N9 or
H7N7 viruses individually. After incubation at room temperature
for 1 h, the fresh prepared 0.5% suspension of Turkey red blood
cells was  added and hemagglutination was assessed by observa-
tion after 1 h. HAI titer is deﬁned as the reciprocal of the highest
dilution that showed ≥50% inhibition of hemagglutination. A titer
of 5 was  recorded if no inhibition at a serum dilution of 1:10.
2.4. Microneutralization assay
The detection of vaccine-induced neutralizing antibody titers
against inﬂuenza viruses were performed with a World Health
Organization recommended protocol. Each RDE-treated serum per-
formed two-fold serial dilutions in a 96-well microtiter plate was
co-incubated with equal volume of virus diluents (100 TCID50/well)
at 37 ◦C for 1 h and then added 1.5 × 104 MDCK cell into each
well to allow virus replication overnight at 37 ◦C in a 5% CO2
incubator. After ﬁxation of the cells, the presence of virus was
detected by enzyme-linked immunosorbent assay (ELISA) with
speciﬁc antibody against NP protein. After tracing with HRP-
conjugated secondary antibody and developed with TMB substrate,
the absorbance was  measured at 450 nm with a Multi-Detection
Microplate Reader (Synergy HT, Bio-Tek). Untreated virus control
(VC), uninfected cell control (CC), and back titration of virus infec-
tivity are included on each plate. Half cell infection was calculated
by the following equation: X = (average OD of VC wells − average
OD of CC wells)/2 + (average OD of CC wells). Microneutralization
titer is expressed as the reciprocal of the highest serum dilution
that showed ≤50% of the cells are infected.
2.5. Mice immunization and virus challenge
Six-weeks-old female BALB/c mice were immunized intramus-
cularly with inactivated virus vaccines (based on HA content
of 0.004 g, 0.02 g, 0.1 g, 0.5 g, 1.5 g, or 3 g) containing
adjuvants or without adjuvants at weeks 0 and 2. AddaVAX is an oil-
in-water emulsion, consisting of the 5% oil squalene, 0.5% Tween 80,
and 0.5% Span-85 in a sodium citrate buffer, with a formulation sim-
ilar to MF59 adjuvant (Norvatis). To prepare Al(OH)3-formulated
vaccine, each dose of vaccine consisted of indicated amount of HA
was mixed with 15 g of Al(OH)3 in sterile phosphate-buffered
saline (PBS; pH 7.1), in a ﬁnal volume of 50 L. Mice antisera were
collected at week 2 or 4 and virus challenge was performed at
week 5. The immunized mice were challenged intranasally with
a lethal dose (100 LD50) of wild-type A/Taiwan/01/2013(H7N9)
inﬂuenza virus and monitored daily for 14 days for survival and
weight loss. All animal experiments were evaluated and approved
by the Institutional Animal Care and Use Committee of Adimmune
Corporation. Mice were euthanized if they exceeded 30% loss of2.6. Statistic analysis
The signiﬁcance in differences between vaccine groups was sta-
tistically computed applying t-test using GraphPad Prism software,
Version 6.0.
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Fig. 1. Characterization and identiﬁcation of inactivated split and whole virus vaccine. (A) The electron micrograph of negatively stained
A/Mallard/Netherlands/12/2000(H7N7)-IBCDC-1 and A/Shanghai/2/2013(H7N9)-IDCDC-RG32A inactivated split or whole viruses. (B) SDS-PAGE analysis of 5 g total
proteins in H7N7 and H7N9 virus vaccines. Puriﬁed HA protein of indicated amount was loaded to calibrate the HA content. S, split virus vaccine; W,  whole virus vaccine. (C)
T lotting using anti–HA antibody to identify the H7 proteins as shown in panel B. HAecto,
2 tting was  prepared by immunizing rabbit with human cell-expressed H7N9 HA protein.
I otech) and Alpha VIEW AS software.
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Table 1
The relative aboundances of HA protein to total protein of vaccine bulks.
Vaccine type H7N7 H7N9
Split (S) Whole (W) Split (S) Whole (W)
HA(%)a 37.0 ± 4.5 35.2 ± 2.3 32.0 ± 1.5 35.5 ± 1.8otal  viral proteins (1 g) and indicated amount of HA was  analyzed by western b
93-F  cell-expressed HA of H7N9 virus. Polyclonal antibody used in the western blo
mages  of SDS-PAGE or western blot were acquired by FluorChem® HD2 (Alpha Inn
. Results
.1. Characterization of H7-type vaccine candidates
In this study, the H7-subtype vaccine candidates were produced
y egg-based process, which has been used as standard method
ince the 1950s to manufacture current licensed inﬂuenza vac-
ines. The morphologies of inactivated H7-subtype whole and split
irus vaccines were negatively stained with 2% uranyl acetate and
bserved using TEM (Fig. 1A). To evaluate the abundance of HA in
accine antigen, the amounts of proteins of each vaccine candidate
nd puriﬁed HAecto protein as determined by BCA protein assay
ere resolved by SDS-PAGE in a 7.5–17.5% gradient gel and then
ubjected to either Coomassie blue staining (Fig. 1B) or western blot
nalyses by speciﬁc antibodies against H7 protein (Fig. 1C). By using
he scanning densitometry, the HA standard curve constructed by
Aecto protein ranging from 3 g to 0.5 g was used to calibrate
he HA content in vaccines. Further, the amounts of HA protein as
ocated by western blotting in vaccine antigens were estimated bya Data are presented as means ± standard deviations from triplicate samples.
interpolation from the calibration curve. After three independent
quantifying experiments, we estimated that the HA protein con-
tributes approximately 32–35.5% and 37–35.2% of total protein of
split/whole H7N9 and H7N7 vaccine, respectively (Table 1). At the
time of this experimentation, the qualiﬁed standard reagents for
single radial immunodiffusion conventionally used to evaluate the
H7N9 vaccine potency were not available. We employed quantita-
tive sandwich ELISA to further quantify the amount of HA antigen in
puriﬁed H7N9 vaccine (Fig. 1, Supplemental). HA protein was  esti-
mated to constitute 33.6% of the total protein in H7N9 split virus
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Fig. 2. Humoral immune response elicited by H7N7 vaccine and cross-reaction of antisera with H7N9 virus. BALB/c mice (n = 5) were immunized with two injections of various
doses  of inactivated virus vaccines as labeled or adjuvant alone as a control. All mice antisera collected at week 2 and week 4 post-priming were tested for seroconversion by
HAI  and microneutralization assays. (A) Antisera were analyzed for HAI titers against H7N7 virus. Comparing the vaccination effect among various formulations, asterisk (***),
(**),  and (*) indicates a signiﬁcant difference (P < 0.001), (P < 0.01), and (P < 0.05), by unpaired t-test. The unlabeled signiﬁcant differences between two groups are presented
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irus.  (C) Antisera were analyzed for cross-reactivity of HAI titers against H7N9 vi
C:  **; FH: **; KM:  **. (D) Antisera from the mice immunized with 0.5 g vaccines w
accine from representative results, consistent with that shown in
able 1.
.2. The immunogenicity of H7N7 antigen combined with various
djuvants
As a preparatory research before acquiring the H7N9 vaccine
train for manufacturing production, we ﬁrst studied its closely
elated virus, H7N7, in terms of immunogenicity and optimiza-
ion of vaccine formulation. A serial of vaccinations in mice were
erformed to address the dose response and adjuvant effects on
7N7 vaccine efﬁcacy which may  serve as references to cali-
rate better vaccine formulation for the pandemic H7N9 strain.
rieﬂy, groups of mice were immunized intramuscularly twice in
wo-week interval with inactivated split or whole virus H7N7 vac-
ine containing Al(OH)3, AddaVAX, or without adjuvant. The sera
rom the mice received 0.5 g (low-dose), 1.5 g and 3 g (high-
ose) vaccines based on HA content were collected at week 2 andd with 0.5 g vaccines were analyzed for neutralizing antibody titers against H7N7
e unlabeled signiﬁcant differences between two groups are presented as follows,
nalyzed for cross-neutralizing antibody titers against H7N9 virus.
week 4 post-priming for further serological assays. As shown in
Fig. 2, only vaccine formulations with the 0.5 g and 1.5 g anti-
gens in AddaVAX-adjuvanted H7N7 whole-virus (lane I and lane
S) can elicit the HAI titers over 40 after ﬁrst vaccination (Fig. 2A,
prime). After the second immunization, the resulting HAI titers
against H7N7 virus illustrated that adjuvants indeed enhanced the
immunogenicity of H7N7 vaccine either with a low-dose or high-
dose vaccination (Fig. 2A). In addition, the squalene-adjuvanted
H7N7 antigens elicited the highest geometric mean with HAI titers
ranging from 320 to 640 among the three experimental groups, sug-
gesting the squalene emulsion is the most efﬁcacious in stimulating
speciﬁc HA antibodies (Fig. 2A). The determination of neutraliz-
ing antibody titers elicited by vaccination may  be more relevant
to the assessment of vaccine efﬁcacy because it is not clear that
all HAI antibodies can accomplish viral-neutralization activity. To
this end, microneutralization assay, as a measurement of antisera
ability to neutralize viral infections to MDCK cells, were per-
formed. The results showed that the mice immunized with vaccines
ine 32 (2014) 4485–4494 4489
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Fig. 3. H7N9 vaccine-induced HA antibody immune response in mice. (A) The end-
point HA antibody titers from the mice immunized with A/Shanghai/2/2013(H7N9)-
IDCDC-RG32A inactivated split or whole virus vaccines were analyzed by using
ELISA. Doses of vaccine antigens and combination with different adjuvants are as
indicated. The unlabeled signiﬁcant differences between two  groups are presented
as  follows, AC: **; EF: *; CD: *; CE: **; QR: ***; GI: ***; MO:  ***; JL: **; HL: ***; GK:
***; GL: ***; HI: ***; HJ: *; IJ: **; MQ:  ***; MR:  *; NO: ***; NP: ***; OR:  ***; PR: ***. (B)C.-Y. Wu et al. / Vacc
ombined with AddaVAX elicited highest neutralizing antibody
iters against H7N7 virus compared with other groups (Fig. 2B).
dditionally, vaccination with 0.5 g AddaVAX-adjuvanted H7N7
accines was shown also to induce signiﬁcant amounts of cross
eactive H7N9-speciﬁc HAI and substantial viral neutralization
iters (Fig. 2C and D). Taken together, the squalene-based adjuvant
as shown great potential to be an effective immune modulator to
mprove the immunogenicity of H7-subtype inﬂuenza virus vac-
ines.
.3. The immune response elicited by H7N9 vaccine
Following the observations with H7N7 vaccine either in split
r whole virus format elicited different levels of immune response
epending on adjuvants reported in the section above, we investi-
ated the speciﬁc anti-HA immunoglobulin (IgG) induced by H7N9
accination in different formats. The ELISA results showed that all
roups of mice vaccinated with H7N9 vaccines exhibited a sig-
iﬁcant response of IgG antibodies against H7 protein (Fig. 3A).
he mice immunized with 0.5 g or above of AddaVAX-adjuvanted
7N9 split virus antigen resulted in higher ELISA mean titers
f 1:40,899–1:56,430 (Fig. 3A, lanes C, I, and O) than AddaVAX-
djuvanted H7N9 whole virus antigen (1:12,500–1:56,430) (lanes
, L, and R). Unlike the observations with H7N7 antigens, the same
osages of both H7N9 vaccine antigens with Al(OH)3 (Fig. 3A,
anes B, E, H, K, N, and Q) or without adjuvants (Fig. 3A, lanes A,
, G, J, M,  and P) also induced ELISA mean titers ranging from
:5,300–1:62,500. Again, it suggested that AddaVAX-adjuvanted
7N9 vaccine may  be a superior formulation to induce robust
umoral immune response speciﬁc to HA of H7N9 virus than
l(OH)3-adjuvantation or without adjuvant.
To characterize whether the vaccine platform play a role in
kewing the cellular immune system toward Th1 or Th2 path-
ay, the isotypes of anti-HA speciﬁc IgG was determined with the
erum sample from each group receiving 0.5 g H7N9 vaccines
ombined with or without adjuvants. Vaccination with H7N9 split
r whole virus vaccine at 4 weeks revealed the dramatic difference
n the ratio of IgG1 and IgG2a (Fig. 3B). Split virus vaccines stim-
lated the strong presence of IgG1 and moderate level of IgG2a
ntibodies, suggestive of a mixed Th1/Th2 response. In contrast,
hole virus vaccines induced an obvious IgG2a antibody response
nly and are indicative of a dominant Th1 response (Fig. 3B). This
cenario described above is consistent with previous study [13].
he results of IgG isotype analysis showed that AddaVAX adjuvant
mproved the vaccine potency, but did not change the pattern of
mmune dominance, and is a more efﬁcacious adjuvant candidate
han Al(OH)3 for development of prophylactic H7N9 vaccines.
.4. The optimization of H7N9 vaccine and protection of mice
gainst viral challenge
To fully investigate the efﬁcacy of H7N9 antigens combined
ith different adjuvants, mice were immunized with H7N9 vac-
ine in a manner similar to that of H7N7 studies. The HAI and
icroneutralization titers against H7N9 and H7N7 viruses were
xamined in sera collected at 4 weeks post-priming (Fig. 4). Vac-
ination with 0.5 g split-virus combined with AddaVAX adjuvant
ere found to have higher HAI antibody titers ≥ 640–1280 (lane
) against H7N9 virus than the Al(OH)3-adjuvanted group which
as HAI ≥160–320 (lane B) or whole-virus combined with adju-
ants with HAI ≥ 320–640 (lanes E and F). Unlike H7N7 vaccines,
he H7N9 split-virus combined with AddaVAX elicited signiﬁcant
igher immunity than whole virus against different H7-subtype
nﬂuenza viruses in mice (Fig. 4, lane C vs. F). The dose-dependent
ffect of vaccination on enhancing HAI titers were not observed inImmunized mice antisera were characterized for IgG1, IgG2a, and IgG2b responses.
Sera were diluted at 1:5000 and analyzed by ELISA using second antibodies against
different IgG isotypes.
the mice groups vaccinated with vaccines dose reaching 1.5 and
3 g (Fig. 4A).
A major purpose for development of H7N9 vaccine is for pre-
pandemic preparation. The adjuvant-dependent does sparing effect
on vaccine antigens is highly desired as it reduces the need for
larger amount of antigens. Our observations that reducing the anti-
gen dose from 3 to 0.5 g did not signiﬁcantly compromise the
immunogenicity of AddaVAX-adjuvanted H7N9 vaccines is in line
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Fig. 4. Humoral immune response elicited by H7N9 vaccine and cross-reaction of antisera with H7N7 virus. BALB/c mice (n = 5) were immunized with different doses of H7N9
split  or whole virus vaccines combined with or without adjuvants as indicated. (A) Vaccine-induced HAI titers against H7N9 virus were detected in antisera. The unlabeled
signiﬁcant differences between two groups are presented as follows, DE: *; AC: ***; GH: *; GI: *; MN:  *; DF: **; MO:  **; JK: *; JL: ***; PR: *; MP:  **; EQ: *; BF: *; MQ:***; MR:
*;  NP: *; NQ:*. (B) Antisera from the mice immunized with vaccines were analyzed for microneutralization titers against H7N9 virus. The unlabeled signiﬁcant differences
between two groups are presented as follows, AB: *; BE: *; GJ: **; AC: **; GH: *; GI: ***; DJ: *; DF: *; MO:  ***; JP: **; BN: *; EK: **; NR: *; MP:  ***; MR:  **; NP: ***; PR: **; GK:
**;  GL: **; IJ: **. (C) Vaccine-induced cross-reactive HAI titers against H7N7 virus were detected in antisera. The unlabeled signiﬁcant differences between two groups are
presented as follows, AB: **; BE: **; GF: **; EQ: *; GH: ***; AC: **; GI: ***; DE: *; IR: ***; DF: **; JK: *; MO:  **; CR: **; JL: ***; BH: *; HL: *; PR: **; BN: *; KG: **; GL: ***; HJ: **;
IJ:  ***; MP:  **; MQ:  **. (D) Antisera were analyzed for cross-neutralizing antibody titers against H7N7 virus. The unlabeled signiﬁcant differences between two groups are
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ith this purpose (Fig. 4A). In contrast, the HAI titers moderately
ecreased in mice when the receiving dosage reduced from 3 to
.5 g whole-virus antigen in the presence of Al(OH)3 adjuvant
lane E vs. lane Q, p < 0.05), indicating a better immune response
licited by Al(OH)3-adjuvanted H7N9 whole-virus vaccine may
eed a higher-dose administration (Fig. 4A).
In parallel, the ability of H7N9 virus vaccine to induce the neu-
ralizing antibodies against H7N9 and H7N7 virus were evaluated
y microneutralization assay. AddaVAX-adjuvanted split vaccine
lane C) elicited signiﬁcantly higher neutralizing antibody titers
han Al(OH)3-adjuvanted split vaccine (lane B, p < 0.05) and adju-
anted whole-virus vaccine (lane E, p < 0.01 and lane F, p < 0.05)
Fig. 4B). Similar results were found in the H7N9 vaccines to induce
he cross-reactive HAI and neutralizing antibodies against H7N7
irus (Fig. 4C and D). The strong correlation between neutralizationF: *; MO: ***; JL: **; PR: ***; EK: *; IO: *; KG: *; GL: ***; IJ: ***; KJ: *; MP:  **; MQ:  **;
and HAI titers for respective H7N9 and H7N7 viruses was signiﬁ-
cant at 0.5 g H7N9 vaccine groups, suggesting the HA antibody
is predominantly responsible for impeding the infectivity of H7N9
and H7N7 viruses (Fig. 4).
To examine the dose-sparing effect of H7N9 vaccine combined
with AddaVAX formulation, additional mice were immunized with
lower-dose of antigen ranging from 0.004 g to 0.1 g to observe
the minimal dose requirement for eliciting signiﬁcant immune
response. The presence of AddaVAX adjuvant in low-dose anti-
gens from 0.004 g to 0.1 g substantially enhanced the H7N9
vaccine efﬁcacy and elicited an adequate immune response against
both H7-subtype viruses similar to the group of 0.5 g antigen
without adjuvant (Fig. 5A–D). Nevertheless, induction of HAI titers
(≥1:40) in immune sera are widely accepted as indicators for
protection of 50% subjects was  achieved by vaccination as little
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Fig. 5. The dose-sparing effect of AddaVAX on antibody responses to H7N9 inactivated whole or split virus vaccines. Mice were immunized with different doses of H7N9
inactivated split or whole virus vaccines combined with AddaVAX as labeled. (A) and (C) Antisera were collected to analyze the HAI titers against H7N9 and H7N7 viruses. (B)
and  (D) The neutralizing antibodies against H7N9 and H7N7 viruses were measured by microneutralization assay. The unlabeled signiﬁcant differences between two groups
are  presented as follows, (A) BC: *; HM:  *; BD: *; CF: *; BF: **; CG: **; IL: ***; AF: *; BG: **; HJ: **; AG: **; DF: *; DG: *; HL: ***: MK: **; ML:  ***. In panel (B) CD: **; HM:  ***; JL:
**;  BD: *; JM:  **; AD: **; CF: **; BF: **; CG: **; IL: **; AF: **; BG: **; HJ: *; IM: **; AG: **; DF: *; DG: *; HL: ***; FL: **; GM: *; BH: *; CJ: *; DJ: **. In panel (C) HM:  *; JL: **; CF: ***;
B *; DG:
* : ***; H
a
s
v
c
t
s
i
v
i
t
v
w
lF:  ***; CG: *; HI: **; IL: **; KM:  **; AF: ***; BG: **; HJ: *; IM:  *; LM:  ***; AG: **; DF: *
**;  FG: *; BF: ***; CG: ***; IL: **; KM:  *; AF: ***; BG: ***; LM:  ***; AG: ***; DF: **; DG
s 0.004 g in AddaVAX-adjuvanted split vaccine against both H7-
ubtype inﬂuenza viruses (Fig. 5A and C). To test whether the
accines offered protective efﬁcacy, the immunized mice were
hallenged with lethal dose (100 LD50) of wild-type H7N9 virus and
he efﬁcacy of vaccine protection was evaluated over 14 d based on
urvival rate and the body weight change. The result showed mice
mmunized with all dosages of split vaccine with adjuvants pro-
ided fully protection against a lethal H7N9 challenge, in contrast to
mmunization with split antigen only provided mice with 60% pro-
ection (Fig. 6A). The mice immunized with 0.5 g of AddaVAX split
accine provided a better protection with a less loss of mice body
eight than other groups and recovered quickly after virus chal-
enge (Fig. 6B). On the other hand, lower dose (0.004 g to 0.1 g) *; HL: ***; FL: **; GM:  **; BH: *. In panel (D) BC: *; HM:  **; JL: ***; BD: **; AD: *; CF:
L: ***; FL: *; GM:  ***; DJ: *.
of split vaccine with AddaVAX and 0.5 g split vaccine with Al(OH)3
compromised the body weight of mice more than 20% loss at Day
3 post-infection and most survivors recovered slower than those
receiving 0.5 g of AddaVAX-split vaccine (Fig. 6B). In summary,
these results indicates the adjuvanation of squalene emulsion in
H7N9 split virus vaccine is the most promising way to optimize the
formulation, achieves better antigen-sparing effect, and provides a
potent protection against H7N9 virus.4. Discussion
In this study, we systematically investigated the H7N9 vac-
cine efﬁcacy and its improvement by combining various doses of
4492 C.-Y. Wu et al. / Vaccine 32
Fig. 6. At week 5 post-priming, vaccinated mice were challenged intranasally with
a  lethal dose (100 LD50) of wild-type H7N9 virus and monitored daily for survival
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vate (A) and weight loss (B). The percentages of survival rate and changes of body
eight were recorded. The used vaccine formulations for challenge studies are as
ndicated.
ntigen with Al(OH)3 or squalene-based adjuvants in mice vac-
ination. To our knowledge, there are no published data on
mprovement of H7-subtype vaccines with squalene adjuvants, as
et. In addition to Al(OH)3 adjuvant, the safety and potency of
qualene-based immunogenic adjuvants such as MF59 has been
iscussed in many human clinical trials [14,15]. To date, it has
een extensively used as formulation for preparedness of current
icensed inﬂuenza virus vaccines [16,17]. Current study not only
roposed a practicable approach but also an alternative formula-
ion to develop effective H7N9 vaccine.
The highly pathogenic avian inﬂuenza A viruses have caused
lobal outbreaks and raised a great concern that further changes
n the viruses may  occur to bring about a deadly pandemic [6]. In
arch 2013, H7N9 avian inﬂuenza virus, like all newly emerged
trains that people have not been exposed to and acquired preexis-
ing immunity, has caused the outbreak of human infections with
ickness and mortality in China. Until now, it’s not fully understood
hat risk factors are involved in the bird-to-human cross-species
ransmission, as well as what might cause pandemics through
iral adaptation to human population. The most cost-effective way
o prevent the spread of highly pathogenic avian inﬂuenza dis-
ases is to induce human immunity by extensive vaccination. Most
f the clinical studies indicated avian inﬂuenza vaccines are less
mmunogenic than seasonal ﬂu vaccine or induce less immunolog-
cal memory in human, thus requiring adjuvantation or two-dose
dministration to improve the vaccine efﬁcacy [18–21]. Although
revious study showed that Al(OH)3-adjuavnted H7N7 whole virus
accine was highly immunogenic, elicited substantial HAI titers, (2014) 4485–4494
and protected the immunized mice from H7N7 viral challenge
[22]. However, the clinical study showed the unadjuvanted split
H7N7 vaccine induced fairly low antibody response with a 36%
seroconverion rate even at high dosage, arguing that H7N7 virus
vaccine antigen is poorly immunogenic in human [12]. Moreover,
the unique low immunogenicity of H7N9 HA has been predicted
by immunoinformatics tool owing to less T-cell epitopes in protein
sequence than circulating inﬂuenza A strains [23]. These reports
highlight the need for more immunogenic vaccine formulations in
H7-subtype vaccine preparations.
For the initial development of H7N9 vaccine, we ﬁrst deter-
mined the kinetics of the humoral immune response to different
doses of H7-subtype inﬂuenza vaccine formulations, including
whole and split virus vaccines combined with or without adju-
vants (Figs. 2–4). Based on previous studies, it is well known that
HA is the major immunogen of vaccines to elicited HAI and viral-
neutralization titers against inﬂuenza viruses. Although the HA
sequence of H7N9 is similar to H7N7 with a high homology of 97%,
split HA antigens from these two  viruses presented a very different
ability to elicit effective humoral immune response. In this study,
H7N7 and H7N9 inactivated whole virus vaccines induced very sim-
ilar level of antibody responses against the same or different type
of H7 viruses (Fig. 2A, lane J vs. Fig. 4A, lane F; Fig. 2C, lane E vs.
Fig. 4C, lane F). In contrast, while H7N7 split vaccine is a very poor
immunogen, which induced negligible HAI titers, and neutraliz-
ing antibodies against both H7-subtype viruses except combined
with adjuvants (Fig. 2), H7N9 split vaccine induced much stronger
immune response either in the presence of or without adjuvants
(Fig. 4). The low immune response to H7N7 split vaccine was also
observed in previous studies in humans and further clariﬁed by
conducting the comparison of HA antigen uptake, processing, pre-
sentation, and trimer conformation as well as the EM morphology
among inﬂuenza vaccines [24]. Interestingly, our TEM observations
showed the H7N7 split vaccine primary exhibited the small round
(5–20 nm)  structures and consistent with the recent report (Fig. 1A
vs. Fig. 5, H7N7 [24]). In contrast, the H7N9 split vaccine showed the
predominant pieces of viral particles of varying sizes, most of that
with external projections of HA and NA (Fig. 1A). This morphology
observed in our H7N9 split vaccine is similar to that of H9N2 split
vaccine described in previous ﬁndings, which also indicated that
H9N2 split antigen is the most immunogenic to induce immune
response among the avian vaccines [24]. All of above observations
support the suggestion that the morphology of vaccine may inﬂu-
ence immunogenicity of split-virion vaccine in human.
The whole virus vaccines were usually used and shown to be
more immunogenic than split virus vaccines [25]. In this study,
we found that without adjuvants, both H7N9 split and whole virus
antigens have compatible immunogenicity (Fig. 4A, lane A vs. lane
D). However, with AddaVAX, the H7N9 split virus vaccine exhib-
ited higher HAI titers and neutralizing capacity to both H7-subtype
viruses than whole virus vaccine (Fig. 4, lane C vs. lane F). No obvi-
ous difference of vaccine potency was  observed among split and
whole virus H7N7 vaccines when combined with individual adju-
vants (Fig. 2A, lane D vs. lane H and lane F vs. lane J). Overall, the
AddaVAX-adjuvanted H7N9 or H7N7 vaccines elicited the highest
HAI and neutralizing antibodies titers when compared to Al(OH)3
or without adjuvant (Figs. 2 and 4). Our results illustrated that
squalene-based adjuvant may  confer the superior formulation to
enhance the H7 subtype vaccine efﬁcacy.
To address the cross-reactivity of H7 subtype vaccines, we
demonstrated that 0.5 g of both AddaVAX-H7N7 vaccines strongly
confer potent cross-reactive HAI and viral neutralizing titers
against H7N9 virus, suggesting the AddaVAX-adjuvantation strat-
egy can enhance the cross-reactivity of H7N7 vaccine (Fig. 2C
and D). On the other hand, the antisera from 0.5 g split- or
whole-virion H7N9 antigen exhibited compatible HAI titer (1:40)
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nd neutralization titers (1:100–300) against both H7-subtype
iruses (Fig. 4). It illustrated that even no adjuvantation, the both
7N9 vaccines also provided adequate HAI titer against H7N7 virus
n mice might due to their highly structure similarity [26] and
ore immunogenic characteristic of HA antigen. Taken together,
his study provided the detailed preliminary assessment of con-
entional H7-subtype virus vaccines efﬁcacy in terms of ﬁnding
ptimal formulation and evaluating the cross-reactivity that may
elp to alleviate the situation of urgent need of effective H7N9
accine during high wave of H7N9 outbreak.
During pandemic situations, the adjuvants may  play a critical
ole in reducing the dose requirement to induce protective immu-
ity in subjects, thereby allowing more people to be vaccinated
ith limited supply. In this study, a dose-sparing effect afford
y squalene-based adjuvant was evaluated by reducing the vac-
ine dose ranging from 3 g to 0.004 g. All of the formulations
ttained an adequate immune response, achieved theoretically pro-
ective HAI titers against H7N9 in mice, and afford substantial
ross-reactive HAI titers against H7N7 viral strain (Fig. 5A–D). To
urther address the vaccine potency, we also evaluate the protec-
ion efﬁcacy in animals. As the humoral immune response induced
y AddaVAX-adjuvanted H7N9 vaccines have reached plateau level
t the doses of 1.5 g and above (Fig. 5, lanes F, G, L, and M),  the pro-
ection of mice against virus challenge were only investigated at the
oses of 0.5 g or less. Virus challenge result showed that 0.5 g or
ower dose (0.004–0.1 g) of AddaVAX-adjuvanted H7N9 split vac-
ine were sufﬁcient to provide 100% protection from death in mice
Fig. 6A). However, the group of mice vaccinated with lower dose
f H7N9-AddaVAX split vaccines exhibited an dramatically body
eight loss (more than 20% of body weight change) in contrast
o the mice group receiving 0.5 g AddaVAX-H7N9 split vaccine
Fig. 6B). This result is consistent with that the 0.5 g AddaVAX-
7N9 split vaccine exhibited signiﬁcantly predominant immune
esponse against H7N9 virus compared with lower-dose groups
Fig. 5A and B, lane E vs. lanes A–D). All above evidences indicate
he squalene-based adjuvantation is a promising way to prepare
or effective H7N9 vaccine for surged demand. Accordingly, we
ighlight that 0.5 g AddaVAX-H7N9 split virus vaccine is the opti-
al  formulation relevant to providing potent immune response
o cross-reaction with H7N7 virus and better protection of mice
gainst H7N9 challenge.
Our results also showed that Al(OH)3 can modestly enhance the
7-subtype antigens immunogenicity to move the dose-response
urve to lower antigen concentration and works slightly better with
igh-dose of whole virus (Fig. 2A, lane H vs. b (p < 0.05) and Fig. 4A,
ane E vs. Q (p < 0.05)) while the squalene-based adjuvant shifts
he optimum immunogenic dose of H7N9 split vaccine at least 10-
old lower (Fig. 5) and could be proven experimentally in a mouse
odel. This phenomenon of squalene-based adjuvant enhancing
he immune response of poorly immunogenic split antigen is in line
ith the observation of previous pre-clinical and clinical studies.
ased on these positive results, we suggested that H7N9 inactivated
irus vaccines combined with squalene-based adjuvant is effective
nd may  increase production capacity to support the demand of
andemic H7N9 inﬂuenza preparedness for human use and further
tudies in humans were warranted to elucidate the vaccine potency
nd optimal formulation.
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